BioCatalyst

OCGN — Ocugen, Inc. catalysts

2 verified catalyst event(s) for Ocugen, Inc. (ticker OCGN). Each is linked to its official source. Verified as of 2026-11-04.

Next verified catalyst

2027-02-12 — A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-02-12
in 3mo
ESTIMATED
 READOUT
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
Phase 3 · Retinitis Pigmentosa
 OCGN Ocugen, Inc. Sub-Retinal Administration of OCU400-301 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2027-03 (month)
in 4mo
ESTIMATED
 READOUT
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and L
Phase 1/2 · Retinitis Pigmentosa, Leber Congenital Amaurosis
 OCGN Ocugen, Inc. OCU400 Low Dose, OCU400 Med Dose, OCU400 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.